Press Release Source: ROTH Capital Partners

ROTH Capital Partners to Host Gene Therapy Corporate Access Day in
New York on October 27, 2015

Event to Feature One-on-One Meetings Between Institutional Investors and
Senior Management Teams Representing Companies Focused on Gene Therapy

NEWPORT BEACH, Calif., October 15, 2015 /BusinessWire/ --- ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Gene Therapy Corporate Access Day on Tuesday, October 27, 2015 at the Lambs Club in New York, NY. 

ROTH's Gene Therapy Corporate Access Day will give investors the opportunity to interact with senior management of a select group of Gene Therapy companies.  There will also be a keynote luncheon by Richard Jude Samulski, Ph.D. on "Transition from Academic to Biotech, Next Steps."

The event will allow for extensive interaction and one-on-one meetings with management teams, providing in-depth insights into each company.

ROTH biotechnology senior research analysts Joe Pantginis, Ph.D., Elemer Piros, Ph.D. and Debjit Chattopadhyay, Ph.D., will be available to discuss their perspectives regarding the companies attending and their views regarding the current biotechnology market trends.

"Gene Therapy has emerged as a highly visible and high growth segment of the biotechnology sector over the past several years.  The companies leading the advancement of Gene Therapy and attending this corporate access day have paved the way for investors to participate in the continuing evolution of this ground-breaking technology," says Joe Pantginis, Ph.D., Senior Biotechnology Research Analyst at ROTH.  "These companies are focusing on the development of therapeutics to target the repair of genetic anomalies at their source or correcting genetic mutation via the delivery of nucleic acid polymers into a patient's cells.  Gene Therapy, with its first human trials dating back to 1990, has evolved rapidly over the past decade and has now demonstrated that the benefits once 'future' technology is realizable today."

"Given the rapid developments and changing dynamics in this sector, our objective of this corporate access day is to provide investors with direct interaction with management teams of a select group of leading Gene Therapy companies," commented John W. Chambers, Vice Chairman and Head of Healthcare Investment Banking at ROTH.  "These companies will be available for one-on-one meetings with investors to present their technology, clinical development strategies, clinical achievements to date and upcoming milestones and catalysts.  The event is intended to enable investors to gain direct insight into the key value drivers for this group of innovative companies."

ROTH has built a leading Healthcare Investment Banking Group over the last several years and has raised approximately $11.8 billion in over 275 Healthcare transactions since 2010. *Past Performance is not indicative of future returns.  (Source: ROTH Capital 10/15/2015)

The event is for institutional clients of ROTH and is by invitation only.  For more information, please contact your ROTH sales representative at (949) 720-5700 or e-mail: conference@roth.com

Agenda and Events:
Tuesday | October 27, 2015
8:00AM - 9:00AM | Registration and Morning Coffee
8:45AM - 9:00AM | Introduction by ROTH Senior Research Analysts
9:00AM - 4:30PM | One-on-One / Small Group Meetings
12:00PM - 1:00PM | Lunch Break
12:15PM - 12:20PM | Introduction by ROTH Senior Biotechnology Analyst, Elemer Piros, Ph.D.
12:20PM 1:00PM | Keynote by Richard Jude Samulski, Ph.D., "Transition from Academic to Biotech, Next Steps."

Venue:
The Lambs Club @ The Chatwal, a Luxury Collection Hotel
130 West 44th Street
New York City, New York 10036

Participating Companies:
The following participating companies are confirmed as of the date of this release.

Abeona Therapeutics Inc. (ABEO)
Applied Genetic Technologies Corporation (AGTC)
Bamboo Therapeutics, Inc. (PRIVATE)
bluebird bio, Inc. (BLUE)
Fibrocell Science, Inc. (FCSC)
GenVec, Inc. (GNVC)
Oxford BioMedica PLC (OXB.L)
Spark Therapeutics, Inc. (ONCE)
uniQure N.V. (QURE)
(10/15/2015 subject to change)

Event sponsors include Business Wire and Lowenstein Sandler LLP

About Roth Capital Partners, LLC:

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit www.roth.com.

Investor and Media Contact:
ROTH Capital Partners
Isabel Mattson-Pain
Director of Marketing and Corporate Access
Imattson-pain@roth.com | 949-720-7117
###